ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

Glaxo To File Experimental Diabetes Drug Albiglutide In Early 2013

By Sten Stovall LONDON--GlaxoSmithKline PLC (GSK) aims to file its experimental once-weekly diabetes drug albiglutide for regulatory approval early next year following the read-out from a series of clinical trials. The British company said Wednesday that top-line data from eight late-stage Phase III clinical studies had now been received and, when taken together, support advancing albiglutide to regulatory submission. Albiglutide is an investigational biological form of human GLP-1 and isn't currently approved anywhere in the world. Human Genome Sciences (HGSI) discovered albiglutide and licensed it to Glaxo for late-stage testing. The drug is a form of GLP-1--a human protein that helps the body maintain normal blood-sugar levels. Glaxo's regulatory filings for albiglutide will be based on a Phase III clinical development program comprising eight individual studies, known as Harmony 1 to Harmony 8, involving some 5,000 patients. The program is investigating the efficacy, tolerability and safety, including cardiovascular safety, of albiglutide as mono- and add-on therapy, in patients with Type 2 diabetes. The latest read out came from Harmony 8, a 52-week study comparing albiglutide with Januvia, made by Merck & Co (MRK). Glaxo said Harmony 8 "is the first completed study of a GLP-1 agonist to assess efficacy and safety across the spectrum of renal impairment from mild to severe, and the third of eight Harmony Phase III studies to complete." It said albiglutide was generally well-tolerated. Results from the eight studies rule out excess cardiovascular risk, according to a threshold prespecified by the U.S. Food and Drug Administration. "Analyses of the data support progression to submission and will be presented to health authorities in the coming months," the company said. Shares in Glaxo closed up 0.8% at 1,465 pence. -Write to Sten Stovall at

Stock News for Merck (MRK)
12/01/201607:00:00FDA Grants Priority Review to Supplemental Biologics License...
11/30/201607:00:00New KEYTRUDA® (pembrolizumab) Data to be Presented at 17th World...
11/29/201607:00:00Actress Bellamy Young, Merck, and Leading Lung Cancer Advocates...
11/28/201607:00:00FDA Grants Priority Review to Merck’s Supplemental Biologics L...
11/28/201600:40:00Amazon Broadens Cloud Services as Big Companies Sign On
11/28/201600:30:00Amazon Broadens Cloud Services as Big Companies Sign On
11/24/201609:29:00House GOP Business-Tax Plan Upends U.S. Policy, Bares Corporate...
11/23/201610:02:00Eli Lilly Alzheimer's Drug Fails Late-Stage Trial -- 3rd Update
11/23/201609:44:00Eli Lilly's Late Stage Alzheimer's Trial Fails To Achieve Goal...
11/22/201613:22:00Merck Announces Increased Quarterly Dividend
11/22/201607:00:00New KEYTRUDA® (pembrolizumab) Data in Blood Cancers to be Presented...
11/18/201613:51:00Sanofi to Stop Production of Bladder-Cancer Drug BCG -- Update
11/18/201611:23:00Sanofi to Stop Production of Bladder-Cancer Drug BCG
11/17/201609:00:00Merck Foundation Announces $10 Million Initiative to Improve...
11/15/201603:30:00Merck Raises Guidance
11/13/201608:00:00Merck Announces Findings for Investigational Triple-Combination...
11/12/201611:45:00Merck’s KEYTRUDA® (pembrolizumab) Significantly Improves Overall Su...
11/12/201608:00:00Merck Announces Presentation of New Findings for ZEPATIER™...
11/10/201617:30:44Statement of Changes in Beneficial Ownership (4)
11/08/201611:52:13Statement of Changes in Beneficial Ownership (4)

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations